Drug · CHEMBL23
DILTIAZEM
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. DILTIAZEM. Drugs and targets, record CHEMBL23. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL23
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets4
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| CACNA1C | Voltage-gated L-type calcium channel | Voltage-gated L-type calcium channel blocker | BLOCKER | https://conductscience.org/library/genes/775 |
| CACNA1D | Voltage-gated L-type calcium channel | Voltage-gated L-type calcium channel blocker | BLOCKER | https://conductscience.org/library/genes/776 |
| CACNA1F | Voltage-gated L-type calcium channel | Voltage-gated L-type calcium channel blocker | BLOCKER | https://conductscience.org/library/genes/778 |
| CACNA1S | Voltage-gated L-type calcium channel | Voltage-gated L-type calcium channel blocker | BLOCKER | https://conductscience.org/library/genes/779 |
Source ChEMBL
Diseases15
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 15Source Open Targets
See all 15 diseasesTrials80
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more that Open Targets linked to it is not shown, since the release's checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT05391893 | Effect of Oral and Intravenous Diltiazem Protocol for Emergency Department Atrial Fibrillation | Phase 4 | 444 | 2024-12-27 | diltiazem | Its name | ClinicalTrials.gov |
| NCT03070470 | CiPA Phase 1 ECG Biomarker Validation Study | Phase 1 | 60 | 2020-01-18 | diltiazem | Its name | ClinicalTrials.gov |
| NCT01914926 | Comparison of Diltiazem and Metoprolol in the Management of Acute Atrial Fibrillation or Atrial Flutter | Phase 4 | 54 | 2013-12-16 | diltiazem | Its name | ClinicalTrials.gov |
| NCT00319982 | Treatment of Preclinical Hypertrophic Cardiomyopathy With Diltiazem | Phase 2/3 | 39 | 2015-04-07 | diltiazem | Its name | ClinicalTrials.gov |
| NCT01151345 | Bioequivalence Study Of Diltiazem In 60 Mg Tablets As Tilazem 60® Made by Pfizer, S.A. De C.V., Versus Angiotrofin® 60 Mg Made by Amstrong Laboratorios De Mexico, S.A. De C.V. | Phase 1 | 26 | 2011-08-22 | diltiazem | Its name | ClinicalTrials.gov |
| NCT04551963 | Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies | Phase 1 | 26 | 2023-11-27 | diltiazem | Its name | ClinicalTrials.gov |
| NCT00983372 | Drug-Drug Interaction Study Between Colchicine and Diltiazem ER | Phase 1 | 24 | 2009-09-24 | diltiazem | Its name | ClinicalTrials.gov |
| NCT02308748 | Ability of Late Sodium or Calcium Current Block to Balance the ECG Effects of Potassium Current Block | Phase 1 | 22 | 2016-06-08 | diltiazem | Its name | ClinicalTrials.gov |
| NCT02319148 | A Study to Estimate the Effect of CYP3A4 Inhibitors (Itraconazole, Diltiazem or Verapamil) on the Pharmacokinetics of Single Dose PF- 00489791 in Healthy Volunteers | Phase 1 | 22 | 2016-09-16 | diltiazem | Its name | ClinicalTrials.gov |
| NCT03472495 | Oral vs Intravenous Diltiazem for Rapid Atrial Fibrillation/Flutter Trial | Phase 4 | 19 | 2023-03-01 | diltiazem | Its name | ClinicalTrials.gov |
1 to 10 of 80
See all 80 trialsComparisons in its trials14
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Diltiazem With Oral and Intravenous Treatment vs Traditional Atrial Fibrillation With Rapid Ventricular Response: Rate of Hypotension | 7 of 177 | 17 of 267 | 444 | NCT05391893 | Trial comparisons |
| Diltiazem With Oral and Intravenous Treatment vs Traditional Atrial Fibrillation With Rapid Ventricular Response: Treatment Success at 3 Hours | 150 of 177 | 192 of 267 | 444 | NCT05391893 | Trial comparisons |
| Diltiazem With Oral and Intravenous Treatment vs Traditional Atrial Fibrillation With Rapid Ventricular Response: deaths from any cause | 0 of 177 | 1 of 267 | 444 | NCT05391893 | Trial comparisons |
| Diltiazem With Oral and Intravenous Treatment vs Traditional Atrial Fibrillation With Rapid Ventricular Response: serious adverse events | 0 of 177 | 0 of 267 | 444 | NCT05391893 | Trial comparisons |
| Diltiazem With Oral and Intravenous Treatment vs Traditional Atrial Fibrillation With Rapid Ventricular Response: Admission Rate | 98 of 172 | 188 of 249 | 421 | NCT05391893 | Trial comparisons |
| Metoprolol Study Group vs Diltiazem Study Group: serious adverse events | 0 of 29 | 0 of 25 | 54 | NCT01914926 | Trial comparisons |
| Tilazem 60 mg vs Angiotrofin 60 mg: serious adverse events | 0 of 25 | 0 of 25 | 50 | NCT01151345 | Trial comparisons |
| I- Diltiazem vs II- Placebo: Development of Left Ventricular Hypertrophy | 2 of 18 | 2 of 20 | 38 | NCT00319982 | Trial comparisons |
| I- Diltiazem vs II- Placebo: serious adverse events | 0 of 18 | 0 of 20 | 38 | NCT00319982 | Trial comparisons |
| Arm A: Zanubrutinib With or Without Moderate CYP3A vs Arm B: Zanubrutinib With or Without Strong CYP3A: deaths from any cause | 1 of 13 | 0 of 13 | 26 | NCT04551963 | Trial comparisons |
1 to 10 of 14
See all 14 comparisons in its trialsPapers from its trials77
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL23
GET https://conductscience.org/api/drugs/v1/CHEMBL23/trials?page=2